CA2346937A1 - Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage - Google Patents

Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage Download PDF

Info

Publication number
CA2346937A1
CA2346937A1 CA002346937A CA2346937A CA2346937A1 CA 2346937 A1 CA2346937 A1 CA 2346937A1 CA 002346937 A CA002346937 A CA 002346937A CA 2346937 A CA2346937 A CA 2346937A CA 2346937 A1 CA2346937 A1 CA 2346937A1
Authority
CA
Canada
Prior art keywords
leu
glu
ser
asp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346937A
Other languages
English (en)
Inventor
Per O. G. Arkhammar
Bernard Robert Terry
Kurt Marshall Scudder
Sara Petersen Bjorn
Ole Thastrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioImage AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2346937A1 publication Critical patent/CA2346937A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne un mécanisme d'action, c'est à dire de modulation de l'efficacité spécifique de kinases I-kappa ou de phosphodiestérases (PDE) de nucléotides cycliques qui peuvent couper un GMPc ou un AMPc. Le mode d'action préféré s'effectue par dislocation, interruption du ciblage ou interférence avec redistribution d'isoformes spécifiques de variants d'épissure de PDE4, PDE5, ou de kinases I-kappa de leurs sites d'ancrage dans des cellules, modulant ainsi leur efficacité spécifique, mais pas leur capacité enzymatique. Les entités chimiques peuvent être utiles dans la prévention ou le traitement chez l'animal, de préférence chez l'homme, dans le besoin, condition défavorable qui peut être réduite ou supprimée par modulation de l'efficacité spécifique de PDE4, PDE5, ou de kinases I-kappa.
CA002346937A 1998-10-15 1999-10-15 Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage Abandoned CA2346937A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199801321 1998-10-15
DKPA199801321 1998-10-15
DKPA199801322 1998-10-15
DKPA199801323 1998-10-15
DKPA199801323 1998-10-15
DKPA199801322 1998-10-15
PCT/DK1999/000567 WO2000023091A2 (fr) 1998-10-15 1999-10-15 Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage

Publications (1)

Publication Number Publication Date
CA2346937A1 true CA2346937A1 (fr) 2000-04-27

Family

ID=27221225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346937A Abandoned CA2346937A1 (fr) 1998-10-15 1999-10-15 Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage

Country Status (5)

Country Link
EP (1) EP1146888A2 (fr)
JP (1) JP2003526608A (fr)
AU (1) AU6189999A (fr)
CA (1) CA2346937A1 (fr)
WO (1) WO2000023091A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
CA2499320A1 (fr) * 2002-09-25 2004-04-08 Decode Genetics Ehf. Gene de predisposition pour l'attaque chez l'homme, et procedes de traitement
CA2519357A1 (fr) * 2003-03-17 2004-09-30 Pfizer Products Inc. Traitement du diabete insulino-dependant a l'aide d'inhibiteurs de pde5
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
KR20150005936A (ko) 2012-04-25 2015-01-15 다케다 야쿠힌 고교 가부시키가이샤 질소화 헤테로시클릭 화합물
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
WO2014142255A1 (fr) 2013-03-14 2014-09-18 武田薬品工業株式会社 Composé hétérocyclique
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
MA49403A (fr) 2017-06-12 2021-03-24 Obsidian Therapeutics Inc Compositions de pde5 et méthodes d'immunothérapie
US11891634B2 (en) 2017-06-23 2024-02-06 The Board Of Trustees Of The Leland Stanford Junior University PDE5A destabilizing domains
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916806D0 (en) * 1989-07-22 1989-09-06 Univ Wales Medicine Modified proteins
AU726383B2 (en) * 1996-08-26 2000-11-02 Signal Pharmaceuticals, Inc. Stimulus-inducible I (KAPPA)B kinase (IKK) signalsome
AU740622B2 (en) * 1997-02-25 2001-11-08 Regents Of The University Of California, The IkB kinase, subunits thereof, and methods of using same
PT1199564E (pt) * 1997-04-07 2004-10-29 Bioimage A S Um metodo para rastrear substancias que tem um efeito na translocacao intracelular
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods

Also Published As

Publication number Publication date
JP2003526608A (ja) 2003-09-09
EP1146888A2 (fr) 2001-10-24
WO2000023091A2 (fr) 2000-04-27
AU6189999A (en) 2000-05-08
WO2000023091A3 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
Houslay et al. The multienzyme PDE4 cyclic adenosine monophosphate–specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
CA2346937A1 (fr) Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage
Luban et al. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
US8658777B2 (en) Activated protease indicator
WO1998045708A1 (fr) Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
CA2246300A1 (fr) Essai a base de cellules
WO2004044168A2 (fr) Rapporteurs fluorescents codes genetiquement presentant des activites de kinase, de methyltransferase et d'acetyltransferase
JP2005525814A (ja) 構成的に転位する細胞系
Márquez-Gómez et al. Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum
US20100048485A1 (en) Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate
Emerit et al. A new mechanism of receptor targeting by interaction between two classes of ligand-gated ion channels
McCahill et al. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases
EP2553453B1 (fr) Outils pour l'identification de ligands de Lingo-1, Lingo-2, Lingo-3 et Lingo-4, et leurs utilisations
US20030228607A1 (en) Screening method and modulators having an improved therapeutic profile
KR100648761B1 (ko) 저산소증-유도성 인자 1α ＨＩＦ-1α 변이체 및ＨＩＦ-1α 조절제의 동정 방법
Tiran et al. Tyrosine phosphatases ε and α perform specific and overlapping functions in regulation of voltage-gated potassium channels in Schwann cells
WO2003008536A2 (fr) Systeme de surveillance d'un processus intracellulaire et criblage in vivo de medicaments
Sumioka et al. The X11L/X11β/MINT2 and X11L2/X11γ/MINT3 scaffold proteins shuttle between the nucleus and cytoplasm
CA2559299C (fr) Sondes pour detecter la migration de proteines dans le noyau et methode pour detecter et quantifier cette migration
CA2219958A1 (fr) Le domaine d'interaction de la sous-unite b de la proteine g de la famille des proteines kinazes ste20p/pak et son utilisation dans les bio-essais
Nauman Structure-Function Analysis of the Tribbles Pseudokinase
Doyle Characterization of calcium regulated adenylyl cyclases
Melnick Structure/function analysis of Drosophila-raf andcorkscrew
US20110275103A1 (en) Emission ratiometric reporters of membrane pdk1 activation
Lv et al. Regulation of Hedgehog Signaling Through Arih2-Mediated Smoothened Ubiquitination and Endoplasmic Reticulum-Associated Degradation

Legal Events

Date Code Title Description
FZDE Dead